메뉴 건너뛰기




Volumn 17, Issue 1, 2019, Pages 93-101

Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; NEW DRUG;

EID: 85054600255     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-018-0434-2     Document Type: Article
Times cited : (8)

References (30)
  • 1
    • 84896721523 scopus 로고    scopus 로고
    • Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
    • Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–8
    • (2014) Lancet Oncol. , vol.15 , Issue.3 , pp. e112-e118
    • Kelly, R.J.1    Smith, T.J.2
  • 3
    • 84975261142 scopus 로고    scopus 로고
    • Value: the next frontier in cancer care
    • Goulart BH. Value: the next frontier in cancer care. Oncologist. 2016;21(6):651–3
    • (2016) Oncologist. , vol.21 , Issue.6 , pp. 651-653
    • Goulart, B.H.1
  • 4
    • 84971623153 scopus 로고    scopus 로고
    • Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis
    • Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032
    • (2016) PLoS Med. , vol.13 , Issue.5
    • Iyengar, S.1    Tay-Teo, K.2    Vogler, S.3    Beyer, P.4    Wiktor, S.5    de Joncheere, K.6
  • 5
    • 84890841035 scopus 로고    scopus 로고
    • Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
    • Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198
    • (2013) Orphanet J Rare Dis. , vol.8 , pp. 198
    • Morel, T.1    Arickx, F.2    Befrits, G.3    Siviero, P.4    van der Meijden, C.5    Xoxi, E.6
  • 6
    • 84910654404 scopus 로고    scopus 로고
    • Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
    • Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47
    • (2015) Soc Sci Med. , vol.124 , pp. 39-47
    • Ferrario, A.1    Kanavos, P.2
  • 8
    • 84949430283 scopus 로고    scopus 로고
    • Monitoring registries at Italian Medicines Agency: fostering access, guaranteeing sustainability
    • Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at Italian Medicines Agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210–3
    • (2015) Int J Technol Assess Health Care. , vol.31 , Issue.4 , pp. 210-213
    • Montilla, S.1    Xoxi, E.2    Russo, P.3    Cicchetti, A.4    Pani, L.5
  • 9
    • 85008481918 scopus 로고    scopus 로고
    • How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries
    • Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–21
    • (2017) Appl Health Econ Health Policy. , vol.15 , Issue.3 , pp. 307-321
    • Vogler, S.1    Paris, V.2    Ferrario, A.3    Wirtz, V.J.4    de Joncheere, K.5    Schneider, P.6
  • 10
    • 85018384674 scopus 로고    scopus 로고
    • Managed entry agreements for oncology drugs: lessons from the European experience to inform the future
    • Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171
    • (2017) Front Pharmacol. , vol.8 , pp. 171
    • Pauwels, K.1    Huys, I.2    Vogler, S.3    Casteels, M.4    Simoens, S.5
  • 12
    • 85060898931 scopus 로고    scopus 로고
    • Accessed 24 Sep 2018
    • HTA. Glossary 2018. www.htaglossary.net. Accessed 24 Sep 2018
    • Glossary 2018
  • 16
    • 85060900421 scopus 로고    scopus 로고
    • Personal communication. 5 Apr
    • Christensen AB. Personal communication. 5 Apr 2018
    • (2018)
    • Christensen, A.B.1
  • 17
    • 4043168324 scopus 로고    scopus 로고
    • Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system
    • Simpson S, Hyde C, Cook A, Packer C, Stevens A. Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system. Int J Technol Assess Health Care. 2004;20(3):381–4
    • (2004) Int J Technol Assess Health Care. , vol.20 , Issue.3 , pp. 381-384
    • Simpson, S.1    Hyde, C.2    Cook, A.3    Packer, C.4    Stevens, A.5
  • 18
    • 34250710525 scopus 로고    scopus 로고
    • Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems
    • Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. Int J Technol Assess Health Care. 2007;23(3):324–30
    • (2007) Int J Technol Assess Health Care. , vol.23 , Issue.3 , pp. 324-330
    • Murphy, K.1    Packer, C.2    Stevens, A.3    Simpson, S.4
  • 19
    • 84866383656 scopus 로고    scopus 로고
    • Analyzing 10 years of early awareness and alert activity in the United Kingdom
    • Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United Kingdom. Int J Technol Assess Health Care. 2012;28(3):308–14
    • (2012) Int J Technol Assess Health Care. , vol.28 , Issue.3 , pp. 308-314
    • Packer, C.1    Fung, M.2    Stevens, A.3
  • 21
    • 85060901128 scopus 로고    scopus 로고
    • (Prepared by the Mathematica Policy Research for ECRI Institute under Contract No. 290-2010-00006-C.) AHRQ Publication No. 16-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality; May
    • Duda N, Fleming C, Kirwan B, Roff B, Rich E. Evaluation of the AHRQ Healthcare Horizon Scanning System. (Prepared by the Mathematica Policy Research for ECRI Institute under Contract No. 290-2010-00006-C.) AHRQ Publication No. 16-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2016. https://www.effectivehealthcare.ahrq.gov/reports/final.cfm
    • (2016) Evaluation of the AHRQ Healthcare Horizon Scanning System
    • Duda, N.1    Fleming, C.2    Kirwan, B.3    Roff, B.4    Rich, E.5
  • 23
    • 85060903690 scopus 로고    scopus 로고
    • Accessed 24 Sep 2018
    • EMA. EMA 2018. www.ema.europa.eu. Accessed 24 Sep 2018
    • (2018)
  • 24
    • 85054562186 scopus 로고    scopus 로고
    • Accessed 24 Sep 2018
    • Swedish eHealth Agency. 2018. https://www.ehalsomyndigheten.se/other-languages/english/. Accessed 24 Sep 2018
    • (2018)
  • 25
    • 85041918897 scopus 로고    scopus 로고
    • The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
    • Eriksson I, Komen J, Piehl F, Malmström RE, Wettermark B, von Euler M. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. Eur J Clin Pharmacol. 2018;74(5):663–70
    • (2018) Eur J Clin Pharmacol. , vol.74 , Issue.5 , pp. 663-670
    • Eriksson, I.1    Komen, J.2    Piehl, F.3    Malmström, R.E.4    Wettermark, B.5    von Euler, M.6
  • 26
    • 85033471480 scopus 로고    scopus 로고
    • Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
    • Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin Pharmacol. 2018;74(2):219–26
    • (2018) Eur J Clin Pharmacol. , vol.74 , Issue.2 , pp. 219-226
    • Eriksson, I.1    Cars, T.2    Piehl, F.3    Malmström, R.E.4    Wettermark, B.5    von Euler, M.6
  • 27
    • 85045086003 scopus 로고    scopus 로고
    • Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
    • Frisk P, Aggefors K, Cars T, Feltelius N, Loov SA, Wettermark B, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018;74(7):971–8
    • (2018) Eur J Clin Pharmacol. , vol.74 , Issue.7 , pp. 971-978
    • Frisk, P.1    Aggefors, K.2    Cars, T.3    Feltelius, N.4    Loov, S.A.5    Wettermark, B.6
  • 28
    • 33845386511 scopus 로고    scopus 로고
    • Selecting new health technologies for evaluation: can clinical experts predict which new anticancer drugs will impact Danish health care?
    • Douw K, Vondeling H. Selecting new health technologies for evaluation: can clinical experts predict which new anticancer drugs will impact Danish health care? Soc Sci Med. 2007;64(2):283–6
    • (2007) Soc Sci Med. , vol.64 , Issue.2 , pp. 283-286
    • Douw, K.1    Vondeling, H.2
  • 29
    • 85054572596 scopus 로고    scopus 로고
    • Accessed 24 Sep 2018
    • The Swedish Early Awareness and Alert System. Shingrix early assessment report 2017. http://www.janusinfo.se/Documents/Nationellt_inforande_av_nya_lakemedel/Shingrix-tidig-bedomningsrapport170519.pdf. Accessed 24 Sep 2018
    • (2017) Shingrix Early Assessment Report


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.